Get started
Author

Yibing Lu

Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
2022 · Dalong Zhu, Xiaoying Li, et al. · Nature Medicine · 94
PDF
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
2022 · Wenying Yang, Dalong Zhu, et al. · Nature Medicine · 73
PDF
Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China
2025 · Jia Sun, Yu Wang, et al. · Arthritis & Rheumatology · 9
PDF
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial
2025 · Dalong Zhu, Jianhua Ma, et al. · Diabetologia · 4
Finerenone in Chinese Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Subgroup Analysis
2026 · Ping Li, Yu An, et al. · Kidney Diseases · 1
PDF
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study
2024 · Linong Ji, Leili Gao, et al. · Current Medical Research and Opinion · 1
Effect of Finerenone on CKD Outcomes in Type 2 Diabetes: A Chinese Subgroup Analysis of the FIDELIO-DKD Study
2022 · Haitao Zhang, Jingyuan Xie, et al. · Journal of the American Society of Nephrology · 1
Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial
2026 · Li Xin, Zhiyong Li, et al. · Osteoporosis International
PDF
Finerenone in Chinese Patients with Type 2 Diabetes and CKD: A FIDELITY Analysis
2023 · Ping Li, Yu An, et al. · Journal of the American Society of Nephrology
Works count: 9
Citation count: 183
H-index: 4
I10-index: 2
Year
Topic
Type